The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute
Issue link: https://lifescienceleadermag.epubxp.com/i/338429
REPORT 30 LIFESCIENCELEADER.COM JULY 2014 CMO SUPPLEMENT EXCLUSIVE LIFE SCIENCE FEATURE Survey Methodology: The Nice Insight Pharma- ceutical and Biotechnology Survey is deployed to outsourcing-facing pharmaceutical and biotechnol- ogy executives on an annual basis. The 2013-2014 re- port includes responses from 2,337 participants. The survey is comprised of 240+ questions and randomly presents ~35 questions to each respondent in order to collect baseline information with respect to cus- tomer awareness and customer perceptions of the top 100+ CMOs and top 50+ CROs servicing the drug development cycle. Five levels of awareness from "I've never heard of them" to "I've worked with them" factor into the overall customer awareness score. The customer perception score is based on six driv- ers in outsourcing: Quality, Innovation, Regulatory, Affordability, Productivity and Reliability. In addi- tion to measuring customer awareness and percep- tion information on specifi c companies, the survey collects data on general outsourcing practices and preferences as well as barriers to strategic partner- ships among buyers of outsourced services. The data showed that among microbial manufacturing CMOs, the companies received their best scores in Reliability and Regulatory. For mammalian cell cul- ture CMOs, the best scores across the group were in Reliability and Innovation. It will be interesting to see from future research if CMOs increase the chances of being considered for a project if they improve on these outsourcing measures. The percentage of new drugs to market that are biologic based continues to rise — from 26 percent of new approvals in 2011 to 29 percent in 2013 — which means it's a good time to identify prospective out- sourcing partners and begin to develop relationships. Consideration of the com- panies mentioned above is a good start, but doing so may end up costing more than joining forces with a smaller, lesser- known CMO. In which case, outsourc- ers of microbial manufacturing can start by looking for contract manufacturers with strong Reliability and Regulatory scores. Those looking to engage a CMO for mammalian cell culture should look for companies with strong Reliability and Innovation scores, or select one of the most frequently considered compa- nies that showed excellence across four categories. L OUTSOURCING BIOMANUFACTURING CONTINUES TO GROW IN FREQUENCY By K. Hammeke Among Respondents Who Will Outsource Biomanufacturing Top Five Companies Considered for Mammalian Cell Culture Projects Top Five Companies Considered for Microbial Manufacturing Projects Mammalian Cell Culture Microbial Manufacturing PERCENTILE RANK PERCENTILE RANK AVERAGE SCORE AMONG TOP 5 AVERAGE SCORE AMONG TOP 5 78% 81% 81% 81% 81% 80% 80% 83% 81% 81% 83% 82% GlaxoSmithKline Biopharmaceuticals Boehringer Ingelheim GmbH CMC Biologics Lonza KBI Biopharma GlaxoSmithKline Biopharmaceuticals Boehringer Ingelheim GmbH Pfizer CentreSource Althea Lonza 97% 97% 94% 91% 88% 99% 95% 94% 74% 68% Quality Reliability Innovation Productivity Regulatory Overall Customer Perception (CP) Score Quality Reliability Innovation Productivity Regulatory Overall CP Score Contact Kate Hammeke at kate.h@thatsnice.com . 0 7 1 4 _ R e s e a r c h _ R e p o r t s _ O I _ B i o 2 . i n d d 6 0714_Research_Reports_OI_Bio2.indd 6 6 / 2 3 / 2 0 1 4 3 : 1 4 : 3 9 P M 6/23/2014 3:14:39 PM